Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

NCT00940225 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

730

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Cancer

Interventions

DRUG: Cabozantinib
DRUG: Placebo

Sponsor

Exelixis